Item(by='gizmo686', descendants=None, kids=[25919755], score=None, time=1611680300, title=None, item_type='comment', url=None, parent=25917644, text='It is a decrease in already low transmission. For ethical reasons, the placebo group is not no treatment, but rather current standard of care.<p>I had to do some digging to find any source on the effectiveness on preventing transmission (the recent FDA approval is for post infection treatment).<p>The study I found is [0]. In a double blinded study of 4,600 participants, half were given the cabotegravir injection, and half were given the daily oral treatment. The study notes a &quot;high level of adherence to oral therapy&quot;; however, the actual numbers on adherence are:<p>&gt; Adherence to oral FTC&#x2F;TDF was high, based on a random subset sampling that detected tenofovir (&gt; 0.31 ng&#x2F;ml) in 87% of all samples tested.<p>I&#x27;m not qualified to say if this actually indicates 87% adherence, or if a fully compliant patient may get a negative result on that test.<p>The result of this study was that 50 particpants got HIV, of which 12 were on the injectable and 38 were on the oral.<p>By my calculation, this gives a relative effectiveness of (38-13)&#x2F;38 = 68.4%, although the paper reports 69%.<p>[0] <a href="https:&#x2F;&#x2F;viivhealthcare.com&#x2F;en-us&#x2F;us-news&#x2F;us-articles&#x2F;2020&#x2F;global-hiv-prevention-study-to-stop-early-after-viiv-healthcares&#x2F;" rel="nofollow">https:&#x2F;&#x2F;viivhealthcare.com&#x2F;en-us&#x2F;us-news&#x2F;us-articles&#x2F;2020&#x2F;gl...</a>')